Sunhongbin

Prof. Sun Hongbin is a second-level professor of China Pharmaceutical University and a Changjiang Scholar of the Ministry of Education. He graduated from the Department of Chemistry of Jilin University in 1989 and obtained his Ph. D. degree from China Pharmaceutical University in 1995. He worked in Germany and the United States for 6 years from 1997 to 2003. He is currently the deputy director of the State Key Laboratory of Natural Medicines, the director of the Innovation Research Institute of China Pharmaceutical University in Chongqing, and the deputy chairman of the Pharmaceutical Chemistry Committee of the Chinese Pharmaceutical Society. His main research interests are the discovery of new drugs in metabolism and immune regulation. Three Class 1 new drugs developed under his leadership have achieved results transfer, among which the new anti-thrombotic drug Vicagagrel has entered phase 3 clinical research and obtained clinical trial approval from the US FDA. More than 200 SCI papers have been published and 30 patents have been authorized. He has presided over more than 20 fund projects such as key projects of the National Natural Science Foundation.

Journal of Medicinal Chemistry, 2022.
British Journal of Pharmacology, 2021

Journal of Medicinal Chemistry, 2021.

Discovery of new drugs for metabolism and immune regulation

Jiangsu Province natural science prize